Table 1

Baseline characteristics by insurance status

VariablesUBMIS
(n=12 445)
NRCMS
(n=10 283)
Self-payment
(n=2213)
P values
Age, mean±SD65.8±12.163.1±11.761.3±13.1<0.0001
Male8320 (66.9)5838 (56.8)1454 (65.7)<0.0001
Education<0.0001
  Elementary or below3926 (31.5)6480 (63.0)1040 (47.0)
  Middle school3131 (25.2)2215 (21.5)483 (21.8)
  High school or above5388 (43.3)1588 (15.4)690 (31.2)
Family monthly income per capita<0.0001
 ≤1000938 (7.5)4088 (39.8)333 (15.0)
 >10008151 (65.5)3399 (33.1)894 (40.4)
  Unknown3356 (27.0)2796 (27.2)986 (44.6)
NIHSS score, median (IQR)3.0 (1.0–6.0)4.0 (2.0–8.0)4.0 (2.0–7.0)<0.0001
NIHSS score, categories<0.0001
  0–46540 (52.6)4683 (45.5)952 (43.0)
  5–144991 (40.1)4642 (45.1)1088 (49.2)
 ≥15914 (7.3)958 (9.3)173 (7.8)
Cerebrovascular disease<0.0001
  Ischaemic stroke9939 (79.9)7654 (74.4)1748 (79.0)
  Transient ischaemic attack1241 (10.0)789 (7.7)125 (5.6)
  Intracerebral haemorrhage1107 (8.9)1639 (15.9)296 (13.4)
  Subarachnoid haemorrhage95 (0.8)169 (1.6)33 (1.5)
  Unspecified63 (0.5)32 (0.3)11 (0.5)
Smoking5473 (44.0)4260 (41.4)987 (44.6)0.0002
Drinking3752 (30.1)2858 (27.8)713 (32.2)<0.0001
Previous stroke/TIA4828 (38.8)3085 (30.0)592 (26.8)<0.0001
Heart failure/MI603 (4.8)294 (2.9)75 (3.4)<0.0001
Hypertension9580 (77.0)7788 (75.7)1671 (75.5)0.0570
Diabetes mellitus3605 (29.0)1877 (18.3)491 (22.2)<0.0001
Dyslipidaemia4374 (35.1)3213 (31.2)580 (26.2)<0.0001
AF1092 (8.8)677 (6.6)185 (8.4)<0.0001
Peripheral artery disease649 (5.2)379 (3.7)118 (5.3)<0.0001
mRS score<0.0001
  0–211 117 (89.3)9398 (91.4)1977 (89.3)
  3–51328 (10.7)885 (8.6)236 (10.7)
Antiplatelets9169 (73.7)7111 (69.2)1481 (66.9)<0.0001
Anticoagulants among AF107/1092 (9.8)80/677 (11.8)17/185 (9.2)0.3391
Tertiary hospital9795 (78.7)5655 (55.0)1747 (78.9)<0.0001
  • AF, atrial fibrillation; MI, myocardial infarction; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NRCMS, New Rural Cooperative Medical Scheme; TIA, transient ischaemic attack; UBMIS, Urban Basic Medical Insurance Scheme.